Clinical Trials
16 trialsT Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
National Institutes of Health Clinical Center (CC)
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
National Institutes of Health Clinical Center (CC)
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
National Institutes of Health Clinical Center (CC)
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
National Institutes of Health Clinical Center (CC)
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)